Hypervirulent strains of Clostridium difficile

Postgraduate Medical Journal

Volumn 83, Issue 979, 2007, Pages 291-295

  Cookson, Barry ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYTOTOXIC AGENT; GATIFLOXACIN; LEVOFLOXACIN; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; CLOSTRIDIUM DIFFICILE; DISEASE SEVERITY; DRUG EXPOSURE; EPIDEMIC; EUROPE; FRANCE; HEALTH CARE DELIVERY; HEALTH SERVICE; INFECTION CONTROL; INFECTIOUS DIARRHEA; NONHUMAN; NORTH AMERICA; RECURRENCE RISK; REVIEW; RISK FACTOR;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; EUROPE; HUMANS; NORTH AMERICA; VIRULENCE;

EID: 34249087190     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.056143     Document Type: Review

References (34)

1. Hall IC, O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935;49:390-402.
2. Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978;298:531-7.
3. Borriello SP. 12th C.L. Oakley lecture. Pathogenesis of Clostridium difficile infection of the gut. J Med Microbiol 1990;33:207-15.
4. Spencer RC. Clinical impact and associated costs of Clostridium difficile-associated disease. J Antimicrob Chemother 1998;41(Suppl C):5-12.
5. Cooke EM, Borriello SP, Brazier JS, et al. DoH, PHLS Working Group. The prevention and management of Clostridium difficile infection. Heywood: BAPS Health Publications Unit, 1994.
6. Larson HE, Borriello SP. Quantitative study of antibiotic induced susceptibility to Clostridium difficile enterocolitis in hamsters. Antimicrob Agents Chemother 1990;34:1348-53.
7. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can Med Assoc J 2004;171:33-8.
8. Nakamura M, Oda M, Akiba Y. Autoradiographic demonstration of lansoprazole uptake sites in rat antrum and colon. J Clin Gastroenterol 1995;20 et al. S8-13. (Suppl 2).
9. Simor AE, Bradley SF, Strausbaugh LJ, et al. Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 2002;23:696-703.
10. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640-5.
11. Loo V, Libman MD, Miller MA, et al. Clostridium difficile: a formidable foe. Can Med Assoc J 2004;171:47-8.
12. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J. 2005 25;173: 1037-42, Also see:http://www.eurosurveillance.org/ew/2005/050630.asp#2 (Accessed 25 Nov 2006).
13. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. C Med Assoc J 2004;171:51-8.
14. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60.
15. McDonald C. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol 2005;26:672-5.
16. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
17. Kuijper EJ. Is Europe prepared for the new emerging Clostridium difficile PCR ribotype O27? ESCMID News. 2006;2: 8-10, http://www.escmid.org/Files/News2_06_72dpi.pdf (accessed 25 Nov 2006).
18. Kuijper EJ, Coignard B, Tüll P, on behalf of the ESCMID Study Group for Clostridium difficile (ESGCD), EU Member States and the European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12(Suppl 6):2-18.
19. Joseph R, Demeyer D, Vanrenterghem D, et al. First isolation of Clostridium difficile PCR ribotype 027, toxinotype III in Belgium. Euro Surveill, 2005;10.http://www.eurosurveillance.org/ ew/2006/060504.asp (accessed 25 Nov 2006).
20. van Steenbergen J, Debast S, van Kregten E, et al. Isolation of Clostridium difficile ribotype 027, toxinotype III in the Netherlands after increase in C. difficile-associated diarrhoea. Euro Surveill. 2005;10: E050714, 1.http://www.eurosurveillance.org/ew/2005/ 050714.asp#1 (accessed 25 Nov 2006), (7).
21. Kuijper EJ, van den Berg RJ, Debast S, et al. Clostridium difficile Ribotype 027, Toxinotype III, the Netherlands. Emerg Infect Dis, 2006;12(5).http://www.cdc.gov/ncidod/eid/vol12no05/05-1350.htm (accessed 25 Nov 2006).
22. van den Hof S, van der Kooi T, van den Berg R, et al. Clostridium difficile PCR ribotype 027 outbreaks in the Netherlands: recent surveillance data indicate that outbreaks are not easily controlled but interhospital transmission is limited. Euro Surveill. 2006;11: E060126, 2.http://www.eurosurveillance.org/ew/2006/060126.asp (accessed 25 Nov 2006), (1).
23. Tachon M, Cattoen C, Blanckaert K, et al. First cluster of C. difficile toxinotype III, PCR-ribotype 027 associated disease in France:preliminary report. Euro Surveill. 2006;11: 5, http://www.eurosurveillance.org/ew/2006/060504.asp (accessed 25 Nov 2006).
24. Barbut F, Delmee M, Brazier J, et al. A European Survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 2003;9:989-96.
25. Indra A, Huhulescu S, Hasenberger P, et al. First isolation of Clostridium difficile PCR ribotype 027 in Austria. Eurosurveillance. 2006;11: 9, http://www.eurosurveillance.org/ew/2006/ 060914.asp (accessed 25 Nov 2006).
26. Anon. Mandatory surveillance of healthcare associated infections report 2006a. Available on http://www.hpa.org.uk/infections/topics_az/hai/ MandSurvHCAI2006.pdf: (accessed 25 Nov 2006).
27. Anon. Report: deaths involving Clostridium difficile: England and Wales; 1999-2004. Health Statistics Quarterly; Spring, 2006b: 56-60, http://www.hpa.org.uk/infections/topics_az/clostridium_difficile/documents/ ReportDeathsinvolvingCdifficile.pdf(accessed 25 Nov 2006)..
28. Anon. Investigation into outbreaks of Clostridium difficile at Stoke Mandeville Hospital, Buckinghamshire Hospitals NHS Trust. July 2006; ISBN: 1-84562-103-4, http://www.healthcarecommission.org.uk/_db/_documents/ Stoke_Mandeville.pdf (accessed 25 Nov 2006).
29. Lemee L, Dhalluin M, Pestel-Caron J, et al. Multilocus sequence typing of human and animal Clostridium difficile isolates of various toxigenic types. J Clin Microbiol 2004;42:2609-17.
30. Stabler RA, Gerding DN, Songer SD, et al. Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J Bacteriol 2006;188: 7297-305.
31. Goorhuis A, Vaessen N, Harmanus C, et al. Interim results of the National Reference Laboratory for Clostridium difficile in the Netherlands. J Hosp Infect. 2006;64(Suppl 1): 4-5, FP2.04.
32. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079- 84.
33. Stone S, Cooper B, Cookson B, et al. The ORION Statement: a CONSORT equivalent for infection control studies - guidelines for transparent reporting of outbreak reports and intervention studies of Nosocomial infection. J Hosp Infect. 2006;64(Suppl 1): 40, P7.02.Draft available on:http://www.bsac.org.uk/_db/_documents/FINAL_ORION.doc.
34. Murchan S, Aucken HM, O'Neil G, et al. Emergence, spread and characterisation of phage variants of epidemic methicillin-resistant Staphylococcus aureus - 16 (EMRSA-16) in England and Wales. J Clin Microbiol 2004;57:345-6.